Literature DB >> 17904680

In vitro assessment of a novel polyrotaxane-based drug delivery system integrated with a cell-penetrating peptide.

Cheol Moon1, Young Min Kwon, Won Kyu Lee, Yoon Jeong Park, Victor C Yang.   

Abstract

In the development of anti-cancer drugs, it is important to yield selective cytotoxicity primarily against tumor tissues. To achieve this goal, the use of a polymer-drug conjugate appears to be appealing, simply because it can take the advantage of the so-called enhanced permeability and retention (EPR) effect due to vascular leak in tumors. Among various types of polymers, polyrotaxane (PR) is an interesting candidate and warrants further consideration. It is a self-assembled polymer made entirely of biocompatible components, by threading alpha-cyclodextrin (alpha-CD) molecules with the poly(ethylene glycol) (PEG) chain. The abundance in functional -OH groups on the CD residues renders PR the capability of carrying a large dose of small anti-tumor agents for delivery. Herein, we presented a novel PR-based delivery system using doxorubicin (DOX) as the model anti-cancer drug. Daunorubicin (DNR) was conjugated to the PR polymer via hydrolysable linkages, and upon hydrolysis, doxorubicin was released as the cytotoxic drug. To facilitate an intracellular uptake by the tumor cells of the PR-DOX conjugates, a cell-penetrating low molecular weight protamine (LMWP) peptide was further attached to the two termini of the PR chain. Using an innovative principle established in our laboratory, such as via the inhibition of the cell-penetrating activity by binding with heparin and reversal of this inhibition by subsequent addition of protamine, cellular uptake of the polymer-drug conjugates could be readily regulated. In this paper, we performed in vitro studies to demonstrate the feasibility of this delivery system. The LMWP-PR-DOX conjugates, which yielded a sustained release of DOX over a period of greater than 4 days, were successfully synthesized. Intracellular uptake of these conjugates by A2780 human ovarian cancer cells and regulation of such uptake by heparin and protamine were confirmed by using the MTT assay and also the confocal microscopy method.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904680      PMCID: PMC2211426          DOI: 10.1016/j.jconrel.2007.08.029

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  27 in total

Review 1.  The taming of the cell penetrating domain of the HIV Tat: myths and realities.

Authors:  Ashok Chauhan; Akshay Tikoo; Arvinder K Kapur; Mahavir Singh
Journal:  J Control Release       Date:  2006-11-17       Impact factor: 9.776

2.  Possible existence of common internalization mechanisms among arginine-rich peptides.

Authors:  Tomoki Suzuki; Shiroh Futaki; Miki Niwa; Seigo Tanaka; Kunihiro Ueda; Yukio Sugiura
Journal:  J Biol Chem       Date:  2001-11-15       Impact factor: 5.157

3.  Paclitaxel delivery systems: the use of amino acid linkers in the conjugation of paclitaxel with carboxymethyldextran to create prodrugs.

Authors:  Shu-ichi Sugahara; Masahiro Kajiki; Hiroshi Kuriyama; To-ru Kobayashi
Journal:  Biol Pharm Bull       Date:  2002-05       Impact factor: 2.233

4.  Targeted PEG-based bioconjugates enhance the cellular uptake and transport of a HIV-1 TAT nonapeptide.

Authors:  S Ramanathan; B Qiu; S Pooyan; G Zhang; S Stein; M J Leibowitz; P J Sinko
Journal:  J Control Release       Date:  2001-12-13       Impact factor: 9.776

Review 5.  Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS.

Authors:  H Maeda; T Sawa; T Konno
Journal:  J Control Release       Date:  2001-07-06       Impact factor: 9.776

Review 6.  PEG drugs: an overview.

Authors:  R B Greenwald
Journal:  J Control Release       Date:  2001-07-06       Impact factor: 9.776

7.  Multivalent interactions between biotin-polyrotaxane conjugates and streptavidin as a model of new targeting for transporters.

Authors:  Tooru Ooya; Nobuhiko Yui
Journal:  J Control Release       Date:  2002-04-23       Impact factor: 9.776

8.  Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells.

Authors:  Francesca Greco; María J Vicent; Siobhan Gee; Arwyn T Jones; Julia Gee; Robert I Nicholson; Ruth Duncan
Journal:  J Control Release       Date:  2006-10-14       Impact factor: 9.776

9.  Fast, efficient and selective deprotection of the tert-butoxycarbonyl (Boc) group using HCl/dioxane (4 m).

Authors:  G Han; M Tamaki; V J Hruby
Journal:  J Pept Res       Date:  2001-10

10.  The effect of the linker on the hydrolysis rate of drug-linked ester bonds.

Authors:  Ronald G Schoenmakers; Petra van de Wetering; Donald L Elbert; Jeffrey A Hubbell
Journal:  J Control Release       Date:  2004-03-05       Impact factor: 9.776

View more
  17 in total

Review 1.  Artificial Molecular Machines.

Authors:  Sundus Erbas-Cakmak; David A Leigh; Charlie T McTernan; Alina L Nussbaumer
Journal:  Chem Rev       Date:  2015-09-08       Impact factor: 60.622

Review 2.  Improved Protein Toxin Delivery Based on ATTEMPTS Systems.

Authors:  Yingzhi Chen; Meng Zhang; Kyoung Ah Min; Huiyuan Wang; Meong Cheol Shin; Feng Li; Victor C Yang; Yongzhuo Huang
Journal:  Curr Drug Targets       Date:  2018-02-19       Impact factor: 3.465

3.  Targeting of Cancer Cells Using Quantum Dot-Polypeptide Hybrid Assemblies that Function as Molecular Imaging Agents and Carrier Systems.

Authors:  Bayu Atmaja; Bertrand H Lui; Yuhua Hu; Stayce E Beck; Curtis W Frank; Jennifer R Cochran
Journal:  Adv Funct Mater       Date:  2010-12-08       Impact factor: 18.808

4.  Paclitaxel-loaded, folic-acid-targeted and TAT-peptide-conjugated polymeric liposomes: in vitro and in vivo evaluation.

Authors:  Peiqi Zhao; Hanjie Wang; Man Yu; Shuzhen Cao; Fei Zhang; Jin Chang; Ruifang Niu
Journal:  Pharm Res       Date:  2010-06-26       Impact factor: 4.200

Review 5.  Cell-penetrating peptides: achievements and challenges in application for cancer treatment.

Authors:  Meong Cheol Shin; Jian Zhang; Kyoung Ah Min; Kyuri Lee; Youngro Byun; Allan E David; Huining He; Victor C Yang
Journal:  J Biomed Mater Res A       Date:  2013-07-30       Impact factor: 4.396

Review 6.  Biocompatible Polymers Combined with Cyclodextrins: Fascinating Materials for Drug Delivery Applications.

Authors:  Bartłomiej Kost; Marek Brzeziński; Marta Socka; Małgorzata Baśko; Tadeusz Biela
Journal:  Molecules       Date:  2020-07-28       Impact factor: 4.411

7.  Enzymatically Biodegradable Polyrotaxane-Deferoxamine Conjugates for Iron Chelation.

Authors:  Zhi Liu; Tien-Min Lin; Max Purro; May P Xiong
Journal:  ACS Appl Mater Interfaces       Date:  2016-09-26       Impact factor: 9.229

8.  Efficient pDNA Delivery Using Cationic 2-Hydroxypropyl-β-Cyclodextrin Pluronic-Based Polyrotaxanes.

Authors:  Vivek Badwaik; Yawo Mondjinou; Aditya Kulkarni; Linjia Liu; Asher Demoret; David H Thompson
Journal:  Macromol Biosci       Date:  2015-08-10       Impact factor: 4.979

Review 9.  Cyclodextrin-based supramolecular systems for drug delivery: recent progress and future perspective.

Authors:  Jianxiang Zhang; Peter X Ma
Journal:  Adv Drug Deliv Rev       Date:  2013-05-11       Impact factor: 15.470

10.  Multi-armed cationic cyclodextrin:poly(ethylene glycol) polyrotaxanes as efficient gene silencing vectors.

Authors:  Aditya Kulkarni; Kyle DeFrees; Ryan A Schuldt; Alexander Vlahu; Ross VerHeul; Seok-Hee Hyun; Wei Deng; David H Thompson
Journal:  Integr Biol (Camb)       Date:  2013-01       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.